| 29.8 0.74 (2.55%) | 03-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 37.16 |
1-year : | 43.4 |
| Resists | First : | 31.81 |
Second : | 37.16 |
| Pivot price | 29.41 |
|||
| Supports | First : | 28.75 |
Second : | 26.86 |
| MAs | MA(5) : | 29.81 |
MA(20) : | 29.6  |
| MA(100) : | 25.66 |
MA(250) : | 19.08 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 56.5 |
D(3) : | 59.2 |
| RSI | RSI(14): 52 |
|||
| 52-week | High : | 31.81 | Low : | 10.6 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ EWTX ] has closed below upper band by 38.1%. Bollinger Bands are 39.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 30.36 - 30.51 | 30.51 - 30.63 |
| Low: | 28.56 - 28.72 | 28.72 - 28.87 |
| Close: | 29.55 - 29.81 | 29.81 - 30.03 |
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Sat, 21 Mar 2026
A Look At Edgewise Therapeutics (EWTX) Valuation After Promising Sevasemten Becker Muscular Dystrophy Data - Sahm
Tue, 17 Mar 2026
Edgewise Therapeutics Inc (EWTX) Stock Price, Quote, News & History - Benzinga
Mon, 16 Mar 2026
First Light Asset Management LLC Lowers Stock Holdings in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Mon, 16 Mar 2026
Edgewise Therapeutics, Inc. $EWTX Shares Purchased by HighVista Strategies LLC - MarketBeat
Sat, 14 Mar 2026
A Look At Edgewise Therapeutics (EWTX) Valuation After Encouraging Long Term Sevasemten Becker Data - Sahm
Sat, 14 Mar 2026
Edgewise Therapeutics (EWTX) Is Up 6.4% After New Long-Term Becker Data On Sevasemten Trial - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 107 (M) |
| Shares Float | 68 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 115.5 (%) |
| Shares Short | 9,490 (K) |
| Shares Short P.Month | 9,420 (K) |
| EPS | -1.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.9 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -23.1 % |
| Return on Equity (ttm) | -34.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.77 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -144 (M) |
| Levered Free Cash Flow | -87 (M) |
| PE Ratio | -18.29 |
| PEG Ratio | 0 |
| Price to Book value | 6.06 |
| Price to Sales | 0 |
| Price to Cash Flow | -22.23 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|